Isolation of Achromobacter xylosoxidans from the respiratory secretions of patients with cystic fibrosis: frequency in the population and significance to the progression of lung disease

W. Balinska-Miskiewicz, K. De Boeck (Leuven, Belgium; Wroclaw, Poland)

Source: Annual Congress 2005 - Cystic fibrosis: genes, inflammation and more
Session: Cystic fibrosis: genes, inflammation and more
Session type: Thematic Poster Session
Number: 2567
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Balinska-Miskiewicz, K. De Boeck (Leuven, Belgium; Wroclaw, Poland). Isolation of Achromobacter xylosoxidans from the respiratory secretions of patients with cystic fibrosis: frequency in the population and significance to the progression of lung disease. Eur Respir J 2005; 26: Suppl. 49, 2567

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis
Source: ERJ Open Res, 5 (4) 00051-2019; 10.1183/23120541.00051-2019
Year: 2019



Cystic fibrosis: Achromobacter xylosoxidans colonized patients have more severe respiratory disease
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013

Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevance
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005


Bacterial infection and lung function in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 615s
Year: 2005

Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections
Source: Eur Respir J 2012; 40: 227-238
Year: 2012



Burkholderia cepacia infection in adult cystic fibrosis patients: Its impact on lung function and survival
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010

Chronic but not intermittent infection with Pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis
Source: Eur Respir J, 50 (4) 1701086; 10.1183/13993003.01086-2017
Year: 2017



DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre
Source: Eur Respir J 2002; 20: Suppl. 38, 208s
Year: 2002

Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa
Source: Eur Respir J 2003; 22: 503-506
Year: 2003



The identification of bacterial strains in specimens of adult cystic fibrosis patients
Source: Eur Respir J 2004; 24: Suppl. 48, 49s
Year: 2004

LATE-BREAKING ABSTRACT: Pseudomonas aeruginosa strain prevalence, adaptation and diversification, during chronic lung infections of UK non-cystic fibrosis bronchiectasis patients
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016

Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006



The spectrum of Nocardia lung disease in cystic fibrosis
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015


Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis
Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Year: 2008


Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients
Source: Eur Respir J 2004; 23: 851-856
Year: 2004



Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis
Source: ERJ Open Res, 4 (2) 00162-2017; 10.1183/23120541.00162-2017
Year: 2018



Screening for cystic fibrosis among high risk group patients with chronic lung disease
Source: Eur Respir J 2002; 20: Suppl. 38, 340s
Year: 2002

Achromobacter xylosoxidans strains with shared genotype among patients attending a cystic fibrosis (CF) rehabilitation centre
Source: Eur Respir J 2005; 26: Suppl. 49, 596s
Year: 2005

Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018